Corona vaccine production makes for record year at AGC Biologics in Denmark

As Covid-19 vaccine orders flooded in, contract manufacturer AGC Biologics achieved a record year in 2021, during which Danish revenue surpassed USD 300m and the bottom line more than doubled.

AGC Biologic's factory in Søborg, Greater Copenhagen, is currently being expanded. | Photo: AGC Biologics

The corona pandemic ended up being a good business opportunity for contract manufacturer (CDMO) AGC Biologics.

The 2021 financial report for the global firm’s Danish division states that revenue generated in the country increased by DKK 730m (USD 100m) to DKK 2.2bn (USD 302m), a figure which represents a 50% increase on 2020’s revenue and more than a doubling of the 2019 bottom line.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs